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This is a cross-sectional, health facility based study. The main objective of this study was 
to estimate the prevalence of HBsAg, HBeAg among pregnant women, attending ANC 
unit in Khartoum state 2005 and the frequency of perinatal transmission of hepatitis 
HBV, and to relate the possible risk factors, in order to use this information to decide 
whether the first dose of HB vaccine to be administered at birth or with DPT-1. 
Three hundred and twenty pregnant women were selected in this study from 20 health 
facilities that provide ANC services in Khartoum state using two stage cluster sample 
technique. 
Women were screened using ELISA test, for hepatitis B surface and e antigen. Where 
(12/320) 3.75% (95% CI: 3.77-3.73) women tested positive for HBsAg and only one 
woman out of the12 rate {8.33 %( 95% CI: 8, 49-8.17)} was hepatitis B e antigen 
positive. Prevalence of HBsAg & HBeAg positive mothers is 0.31%, Frequency of HBV 
carriers in population due to perinatal infection is 0.25%. In relating the r risk factors for 
HBV to the prevalence of HBV, the relation was found to be statistically insignificant. 
It was concluded that there is moderate endemicity of HBV infection and low perinatal 
transmission of the disease In Khartoum state. 
It is thus recommended to continue giving the HBV vaccine with the DPT as scheduled, 
to conduct other studies for young children to define the relative importance of perinatal 
versus childhood transmission, to screen all pregnant women for HBV during antenatal 
care visits, and giving appropriate management for neonates of +ve mothers, and to study 
the prevalence in other states. 
 




ﻣﻮﻟﺪ اﳌﻀﺎد اﻟﺴﻄﺤﻲ وﻣﻮﻟﺪ اﳍﺪف اﻟﺮﺋﻴﺴﻲ ﻣﻦ هﺬﻩ اﻟﺪراﺳﻪ هﻮ ﺗﻘﺪﻳﺮ ﻣﺪى اﻧﺘﺸﺎر 
اﻟﻼﺋﻲ  ﺑﲔ اﻟﻨﺴﺎء اﳊﻮاﻣﻞ  ﻟﻔﲑوس اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﲑوﺳﻲ اﻟﺒﺎﺋﻲاﻟﻐﻼﰲاﳌﻀﺎد 
وﻣﻦ اﻻهﺪاف اﻻﺧﺮى  ،5002 اﳋﺮﻃﻮم ﻋﺎم ﻳﱰددن ﻋﻠﻲ ﻋﻴﺎدات رﻋﺎﻳﺔ اﳊﻤﻞ ﺑﻮﻻﻳﺔ
 اﻟﺮﺑﻂ ﺑﲔ آﺬﻟﻚ ﳏﺎوﻟﺔ ،  اﻟﻔﲑوﺳﻲ اﻟﺒﺎﺋﻲل اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻧﺘﻘﺎ ﺗﻮاﺗﺮﺗﻘﺪﻳﺮ
هﺬﻩ اﳌﻌﻠﻮﻣﺎت ﺳﺘﻜﻮن ﻣﻔﻴﺪة ﰲ ﲢﺪﻳﺪ ﻣﺎ اذا آﺎﻧﺖ اﳉﺮﻋﻪ ان  ﺑﺈﻋﺘﺒﺎرﻋﻮاﻣﻞ اﳋﻄﺮ 
 ﻋﻨﺪ اﻟﻮﻻدة اوﻟﻼﻃﻔﺎل  ﳚﺐ ان ﻳﻌﻄﻰ  اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﲑوﺳﻲ اﻟﺒﺎﺋﻲاﻻوﱃ ﻣﻦ ﻟﻘﺎح
  .(اﻟﺸﻠﻞ، اﻟﺘﺘﻨﺲ واﻟﺪﻓﺘﲑﻳﺎ) ﻣﻊ اﻟﻠﻘﺎح اﻟﺜﻼﺛﻲ
 ﻣﻦ اﳌﺮاﻓﻖ اﻟﺼﺤﻴﺔ 02ﰲ ﺬﻩ اﻟﺪراﺳﻪ ﳍ ناﳊﻮاﻣﻞ اﺧﱰاﻟﻨﺴﺎء   ﻣﻦﻪ وﻋﺸﺮونﺋﺛﻼﲦﺎ
وﻗﺪ ﰎ اﺧﺘﻴﺎر اﻟﻌﻴﻨﺔ .ﰲ دراﺳﺔ ﻣﻘﻄﻌﻴﺔﰲ اﳋﺮﻃﻮم رﻋﺎﻳﺔ اﳊﻤﻞ اﻟﱴ ﺗﻘﺪم ﺧﺪﻣﺎت 
 .ﻣﺮﺣﻠﺘﲔﺑﻄﺮﻳﻘﺔ ﻋﻨﻘﻮدﻳﺔ ﻣﻦ 
ى ﻼﻟﺘﻬﺎب اﻟﻜﺒﺪﻟﻀﺎدات اﳌ ﻟﻠﻜﺸﻒ ﻋﻦ وﺟﻮد ﻣﻮﻟﺪات ﻨﺴﺎء اﳊﻮاﻣﻞاﻟاﺧﺘﱪت ﻋﻴﻨﺎت ﻣﻦ 
  ٪59وﺑﺎﺑﻌﺎد ﺛﻘﺔ ﻋﻨﺪ(023/21)٪ 57.3 ﺣﻴﺚ وﺟﺪ أن ﻣﻌﺪل اﻻﻧﺘﺸﺎر ﻳﺴﺎوي. اﻟﺒﺎﺋﻲ
 اﻟﻐﻼﰲﻣﻮﻟﺪ اﳌﻀﺎد اﳚﺎﺑﻴﺔ ﻻﺧﺘﺒﺎر ﻴﺠﺔﺘأة واﺣﺪة ﻧﻣﺮﺑﻴﻨﻤﺎاﻋﻄﺖ ا (37.3-77.3): 
وﺑﺎﺑﻌﺎد ﺛﻘﺔ  ٪ 33.8ﻟﻔﲑوس اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﲑوﺳﻲ اﻟﺒﺎﺋﻲ ﲟﻌﺪل اﻧﺘﺸﺎر ﻳﺴﺎوي 
ل اﻻﻧﺘﺸﺎر ﻟﻠﻨﺴﺎء اﻟﻠﻮاﺗﻲ اﻋﻄﲔ ﻧﺘﺎﺋﺞ اﳚﺎﺑﻴﺔ وأن ﻣﻌﺪ(. 71.8-94.8) : ٪ 59ﻋﻨﺪ
 . ٪13.0آﺎن اﻟﺒﺎﺋﻲﻟﺘﻬﺎب اﻟﻜﺒﺪي ﻻاﻟﻐﻼﻓﻴﺔ ﻣﻌًﺎاﻟﺴﻄﺤﻴﺔ و ﻀﺎدات اﳌ ﳌﻮﻟﺪات
.  ٪52.0 ﻣﻦ اﻻﻣﻬﺎت اﱄ اﻻﻃﻔﺎل اﺛﻨﺎء اﳊﻤﻞ واﻟﻮﻻدة آﺎناﻻﺻﺎﺑﺔ  لﺎﻘﺘﻧاﺗﻮاﺗﺮ و
 .اﺣﺼﺎﺋﻴﺎﻮﻳﺔ ﻗاﻟﻌﻼﻗﺔ ﻓﻠﻢ ﺗﻜﻦ ، ﺑﺔاﻻﺻﺎﲟﻌﺪل ﻄﺮ اﳋ ﻋﻮاﻣﻞ  ﺑﻌﺾورﺑﻂ اﻟﺒﺤﺚ
ﻣﻦ ﰒ و.  اﳌﺮض ﰲ وﻻﻳﺔ اﳋﺮﻃﻮمﻣﺴﺘﻮى ﻣﺘﻮﺳﻂ ﻟﺘﻮﻃﻦان هﻨﺎك ﺤﺚ ﻣﻦ اﻟﺒاﺳﺘﻨﺘﺞ ﻗﺪو
 ﻣﻊ اﻟﻠﻘﺎح ﻼﻃﻔﺎل آﻤﺎ آﺎن ﻣﻘﺮراﻟ اﻟﻜﺒﺪ ﲟﻮاﺻﻠﺔ اﻋﻄﺎء ﻟﻘﺎح اﻟﺘﻬﺎب ﺔﻮﺻﻴاﻟﺘ ﲤﺖ
  ﻟﺘﺤﺪﻳﺪ اﻻﳘﻴﻪ اﻟﻨﺴﺒﻴﻪﻻﻃﻔﺎلﰲ ااﺟﺮاء دراﺳﺎت اﺧﺮى ﻣﻊ ﺿﺮوة، اﻟﺜﻼﺛﻲ
ﻔﺤﺺ ﲨﻴﻊ اﻟﻨﺴﺎء اﳊﻮاﻣﻞ ﺑ آﺬﻟﻚ أوﺻﻰ،  ﻣﻘﺎﺑﻞ ﻓﱰة اﳊﻤﻞﻟﺔﻓﱰة اﻟﻄﻔﻮﻟﻼﺻﺎﺑﺔاﺛﻨﺎء 
 اﻟﺘﻤﻜﻦ ﻣﻦ اﳊﻮاﻣﻞ ﻟﺘﺤﺪﻳﺪ اﻻﺻﺎﺑﺔ ﺑﺎﳌﺮض،وﻣﻦ ﰒرﻋﺎﻳﻪ ﻣﺮاآﺰ ﻋﻠﻰ اﻟﻼﺋﻲ ﻳﱰددن 
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Hepatitis is an inflammation of the liver. It is usually caused by viral infection, toxic 
agents or drugs but may be an auto immune response.1 
Hepatitis B is a serious disease caused by a virus that attacks the liver. The virus, which is 
called hepatitis B virus (HBV), can cause lifelong infection, cirrhosis (scarring) of the 
liver, liver cancer, liver failure, and death.2 
It was estimated that approximately 2 billion people have serological evidence of past or 
present HBV infection. More than 350 million are chronic carriers of HBV. 
Approximately 75% of chronic carriers live in Asia and the Western Pacific It was 
reported that 15-40% of HBV infected patients would develop cirrhosis, liver failure, or 
HCC ,and   500, 000 to 1.2 million people die of HBV infection annually.3 
The frequency and patterns of HBV transmission vary markedly in different parts of the 
world. Approximately 45% of the world's population live in areas where the prevalence 
of chronic HBV infection is high (>8% of the population is HBsAg-positive); 43% live in 
areas where the prevalence is moderate (2%–7% of the population is HBsAg-positive); 
and 12% live in areas of low endemicity (<2% of the population is HBsAg-positive).4 
Most studies in Sudan suggest there is a higher prevalence of HBV infection among 
residents of the south compared with those of the north.  Overall, most studies indicate 
that there is high endemicity in Sudan with a prevalence of chronic infection ranging 
from 4% to 30 %.4 
HBV is spread through contact with infected body fluids and the only natural host is 
human. Blood is the most important vehicle for transmission, but other body fluids have 
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also been implicated, including semen and saliva. Currently, three modes of HBV 
transmission have been recognized: perinatal, sexual and parenteral / percutaneous 
transmission. There is no reliable evidence that airborne infections occur and feces are 
not a source of infection. HBV is not transmitted by contaminated food or water, insects 
or other vectors.5 
The main risk factors for hepatitis B are engaging in unsafe sex, particularly unprotected 
receptive anal sex, having sex with more than one partner or with a partner who has or 
has had more than one partner or who uses or has used IV drugs, sharing needles, recent 
history of STI infection, having a blood transfusion or treatment with infected blood 
products, getting a tattoo or piercing, having a job (such as a health care worker) that 
exposes one to blood or other body fluids, traveling or living in areas with high rates of 
HBV infection (including Southeast Asia, the Amazon basin in South America, the 
Pacific Islands,  and the Middle East)6 
Prevention is the only safeguard against the epidemic of viral hepatitis. The best way to 
prevent hepatitis B is to avoid the practices that increase the risk of infection. Knowing 
the facts and having proper attitudes and behaviors are also critical to prevent the spread 
of these infections. Family practitioners who work as primary and first level health care 
providers and who are engaged with patients and their families in the areas of prevention, 
cure and care can play an important role by increasing public awareness and 
understanding of these diseases.7 
Advisory Group to the World Health Organization recommended that all countries 
integrate hepatitis B vaccine into national immunization programs by 1997. Currently, 
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80 countries have done so and several others are planning to. Many countries have 
reported dramatic reductions in the prevalence of chronic HBV infection among children 
born since the hepatitis B vaccine was introduced into infant immunization schedules. 
Recent reports from Taiwan indicate a reduction in the incidence of liver cancer among 
children as a result of widespread hepatitis B vaccination programs.8 
Hepatitis B vaccine has been introduced into Sudan’s routine immunization programme 
by the year (2004) in 3 states which are Khartoum, Gezira and Blue Nile states. The 
vaccine is given as 3 doses at 6, 10 and 14 months with the three doses of DPT .9 
Justification  
Hepatitis B vaccine has been introduced into Sudan’s routine immunization programme in 
the year (2004), so, knowing the prevalence of HBsAg and HBeAg among pregnant 
women will reveal the relative importance of mother –to-child transmission in the 
population and this information will be useful in deciding whether the first dose of HB 
vaccine to be administered at birth or with DPT-1. 
Also Information obtained from one’s own country may be more convincing to policy – 
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General objective: 
To study the distribution and determinants of hepatitis B virus infection among pregnant 
women attending ANC units in Khartoum state 2005. 
 Specific objectives: 
1/ To measure the prevalence rate of HBs &e Ag among pregnant women, attending 
ANC unit in Khartoum state 2005.  
2/ To relate the prevalence of HBV infection to risk factors and socio demographic 
factors (age, education, race, multiple sexual partners, blood transfusion, unsafe injection, 
history of jaundice, history of renal dialysis, risky work, family size) . 
3/ to estimate the proportion of perinatal transmission of hepatitis BV. 
4/to define the socio-demographic factors associated with HBV infection among pregnant 
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Hepatitis B is endemic throughout the world, especially in tropical and developing 
countries. Its prevalence varies from country to country and depends upon a complex mix 
of behavioral, environmental and host factors.  In general it is lowest in countries or areas 
with high standards of living, sixty six percent of all worlds’ population live in areas 
where there is high level of infection .11 
The distribution of hepatitis B infection varies greatly throughout the world. In areas 
where the prevalence is high, such as Southeast Asia, China, and Africa, more than half 
the population is infected at some time in their lives, and more than 8 percent are chronic 
carriers of the virus, the result of either neonatal transmission (vertical) or transmission 
from one child to another (horizontal). Areas with low levels of endemicity include North 
America, Western Europe, and Australia, where only a minority of people come into 
contact with the virus, as a result of horizontal transmission among young adults. The 
World Health Organization estimates that the number of HBV carriers will reach 400 
million by the year 2000. The numbers will continue to increase until neonatal 
vaccination and immunization are universally accepted.12 
The largest reported outbreak of hepatitis B was in 1942 during World War II when 
28,585 American soldiers inoculated with yellow fever vaccine developed jaundice and 
62 of them died.  This outbreak was linked to a specific vaccine that contained human 
serum.13 A follow-up study in the 1980s demonstrated that 97% of recipients of the 
serum-containing vaccine had serological evidence of hepatitis B virus (HBV) infection 
compared with 13% of people who received yellow fever vaccine that did not contain 
human serum, thus confirming that HBV was the cause of this outbreak.13  
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The groundbreaking studies of Krugman and colleagues in 1967 firmly established the 
existence of at least two types of hepatitis, one of which (then called serum hepatitis, and 
now called hepatitis B) was parenterally transmitted. Links to the virus responsible for 
this form of hepatitis were derived by serologic studies conducted independently by 
Prince and colleagues and by Blumberg and colleagues.14 Blumberg and colleagues, 
searching for serum protein polymorphisms linked to diseases, identified an antigen 
termed Australia antigen (Au) in serum from patients with leukemia, leprosy, and 
hepatitis, though the relationship of this antigen to hepatitis was initially unclear. By 
systematically studying patients with transfusion-associated hepatitis, Prince and 
coworkers independently identified an antigen, termed SH, that appeared in the blood of 
these patients during the incubation period of the disease, and further work established 
that Au and SH were identical.14 The antigen represented the hepatitis B surface antigen 
(HBsAg). These seminal studies made possible the serologic diagnosis of hepatitis B and 
opened up the field to rigorous epidemiologic and virologic investigation.14 
A few years later, in 1970, Dane visualized the hepatitis B virus (HBV) virion. Since 
then, considerable progress has been made regarding the epidemiology, virology, natural 
history, and treatment of this hepatotropic virus.15 
Hepatitis B virus is a DNA virus of hepadnaviridae family of viruses. It replicates within 
infected liver cells (hepatocytes).16It is an extremely resistant strain capable of 
withstanding extreme temperatures and humidity. It can survive when stored for 15 years 
at -20°C, for 24 months at -80°C, for 6 months at room temperatures, and for 7 days at 
44°C.5 
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The virus is a spherical particle with a diameter of 42nm and is composed of an outer 
shell composed of several proteins known collectively as HBs or surface proteins, and 
this outer shell is frequently referred to as the surface coat16. Hepatitis B surface antigen 
(HBsAg) is a protein antigen produced by HBV. This antigen is the earliest indicator of 
acute hepatitis B and frequently identifies infected people before symptoms appear. 
HBsAg disappears from the blood during the recovery period17. In some people 
(particularly those infected as children or those with a weak immune system, such as 
those with AIDS), chronic infection with HBV may occur and HBsAg remains positive.17 
The presence of hepatitis B surface antibody (anti-HBs) is an indicator of previous 
exposure to HBV, but the virus is no longer present and the person cannot pass on the 
virus to others. The antibody also protects the body from future HBV infection. In 
addition to exposure to HBV, the antibodies can also be acquired from successful 
vaccination. This test is done to determine the need for vaccination 17(if anti-HBsAg is 
absent), or following the completion of vaccination against the disease, or following an 
active infection. 17 Then follows the outer surface coat surrounds an inner protein shell. 
composed of HBc protein , this inner shell is referred to as the core particle .The core 
particle surrounds the viral DNA ( D ) and an enzyme DNA polymerase ( p ) .16 The core 
antigen, HBcAg, is the protein that encloses the viral DNA. It also can be expressed on 
the surface of the hepatocytes, initiating a cellular immune response.17 Anti-hepatitis B 
core antigen (anti-HBc) is an antibody to the hepatitis B core antigen. The core antigen is 
found on virus particles but disappears early in the course of infection. This antibody is 
produced during and after an acute HBV infection and is usually found in chronic HBV 
carriers as well as those who have cleared the virus, and usually persists for life. Anti-
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HBcAg testing is either specific for the IgM antibody, anti-HBc, IgM, which indicates 
acute infection, or measures total antibody, anti-HBC, which indicates past infection, 
either acute or chronic.18 The e antigen, HBeAg, comes from the core gene and is a 
marker of active viral replication. Usually, HBeAg can be detected in patients with 
circulating serum HBV DNA17. Unlike the surface antigen, the e-antigen is found in the 
blood only when there are viruses also present. When the virus goes into “hiding,” the e-
antigen will no longer be present in the blood. HBeAg is often used as a marker of ability 
to spread the virus to other people (infectivity). Measurement of e-antigen may also be 
used to monitor the effectiveness of HBV treatment; successful treatment will usually 
eliminate HBeAg from the blood and lead to development of antibodies against e-antigen 
(anti-HBeAg).18 
Anti-HBeAg is an antibody produced in response to the Hepatitis B e antigen. In those 
who have recovered from acute hepatitis B infection, anti-HBeAg will be present along 
with anti-HBcAg and anti-HBs. In those with chronic hepatitis B, usually anti-HBeAg 
becomes positive when the virus goes into hiding or is eliminated from the body. In 
strains that do not make HBe antigen, anti-HBeAg is also positive.18 
There are several tests used to detect the presence of hepatitis B viral antigens. 
HBsAg is the most commonly used marker of infection for diagnostic and blood 
screening. An individual positive for HBsAg is considered to be infected with HBV, and 
is therefore potentially infectious. Confirmation of a reactive HBsAg ELISA screening 
test is usually done by performing a neutralization test using a specific anti-HBs 
antiserum in the same screening ELISA. Where a simple/rapid HBsAg test is used and no 
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neutralization reagents are available, confirmation of an acute or chronic infection for 
diagnostic purposes may be concluded based upon symptoms and appropriate monitoring 
tests. Other HBV markers which can be used diagnostically to monitor an HBV infection 
include HBeAg. The presence of HBeAg indicates an individual is of higher infectivity, 
and sero-conversion to anti-HBeAg correlates with reduced infectivity. In an acute 
infection this suggests that the infected person is progressing towards resolving their 
infection. Individuals who have sero-converted from HBsAg to anti-HBs have resolved 
their infection and are immune to further HBV infection.19 
The most widely used HBsAg screening test worldwide is ELISA as they are the most 
appropriate for screening large numbers of specimens on a daily basis, as is the case in 
blood transfusion services in industrialized countries. Several simple, instrument and 
electricity-free screening tests have been developed including agglutination, immune-
filtration (flow through) and immuno-chromatographic (lateral flow) membrane tests. In 
general, these simple/rapid (S/R) tests are most suitable for use in laboratories that have 
limited facilities and/or process low numbers of specimens daily.19 Care should be taken 
however to ensure that the test meets any regulatory specifications, e.g. in some countries 
the use of tests with a minimum detection level of 0.5ng/ml HBsAg for testing of donated 
blood is mandatory. The probability that a test will accurately determine the true infection 
status of a person being tested varies with the prevalence of HBV infection in the 
population from which the person comes. Generally, the higher the prevalence of HBV 
infection in the population, the greater the probability that a person testing positive is 
truly infected (i.e. the greater the positive predictive value [PPV]). Thus, with increasing 
prevalence, the proportion of serum samples testing false-positive decreases; conversely, 
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the likelihood that a person showing negative test results is truly uninfected (i.e. the 
negative predictive value [NPV]), decreases as prevalence increases. Therefore, as 
prevalence increases, so does the proportion of samples testing false negative.19 
The principal screening test for detecting current HBV infection or carrier state in 
asymptomatic persons is the identification of hepatitis B surface antigen (HBsAg). The 
immunoassay for detecting HBsAg has a reported sensitivity of 97.5 percent and a 
specificity of 98 percent. Spontaneous clearance of HBsAg occurs each year in 1 to 2 
percent of the carriers19. 
The course of hepatitis B may be extremely variable. Hepatitis B virus infection has 
different clinical manifestation depending on the patient’s age at infection and the 
immune status, and the stage at which the disease is recognized .20 
The spectrum of the symptomatology varies from subclinical hepatitis, icteric hepatitis to 
hyperacute, acute, and subacute hepatitis during the acute phase and from an 
asymptomatic carrier state to chronic hepatitis, cirrhosis, and HCC during the chronic 
phase.17 About 30% of persons have no signs or symptoms. Signs and symptoms are less 
common in children than adults.21 
Acute HBV infection is subclinical in 70 percent of adults and 90 percent of children 
younger than five years. The incubation period after infection lasts one to four months. 
Symptoms of acute HBV infection include nausea, anorexia, fatigue, low-grade fever, 
and right upper quadrant or epigastric pain. Clinical jaundice appears as constitutional 
symptoms are resolving. Extrahepatic manifestations of acute HBV infection include 
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myalgias, joint pain, and urticaria. Symptoms of acute disease resolve by one to three 
months, although some persons have prolonged fatigue. Treatment for acute infection is 
generally supportive, although some patients require hospitalization22. Most adults get 
better in a few weeks or a few months. Some adults (and more children and babies) feel 
like they are getting better, but the virus stays in their liver. These people have chronic 
HBV infection23. 
Chronic HBV infection is defined as hepatitis B surface antigen (HBsAg) positivity for at 
least six months. Current thinking endorses the concept of four distinct stages of HBV 
infection, which may be used to describe acute and chronic disease23.  
The first stage, the "immune tolerant" phase, is characterized by high levels of HBV 
DNA replication, hepatitis B e antigen (HBeAg) positivity, and normal serum 
transaminase levels. In the acutely infected child or adult, this stage represents the 
incubation period before immune response to HBV. In neonates, the immune-tolerant 
stage may last for years to decades23. 
The second stage reflects the "immune response," which is the inflammatory process that 
results in the destruction of HBV-infected cells, elevating transaminase levels. 
Persistence of the immune response phase beyond six months is considered chronic HBV 
infection. This stage carries the highest risk of progression to cirrhosis and hepatocellular 
carcinoma23. 
The third stage, the "inactive carrier" state, is thought to mark the end of active viral 
replication. HBeAg becomes negative, hepatitis B e antibody (anti-HBeAg) appears 
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(sero-conversion), and transaminase levels normalize. A low level of HBV DNA still 
may be present. The majority of adults with acute HBV infection enter this stage rapidly. 
In most chronically infected neonates and some children and adults, the conversion rate is 
5 to 15 percent per year; a higher rate is associated with increasing age and elevated ALT 
levels. From 10 to 30 percent of carriers will have disease flares similar to acute HBV 
infection23. 
The fourth, or "immune," stage is characterized by the clearance of HBsAg. HBV DNA is 
usually undetectable, and reactivation or reinfection is uncommon. Progression from the 
third to the fourth stage occurs in approximately 3 percent of HBV-infected persons per 
year23.  
HBV can be transmitted at perinatal, childhood or adult ages. The main modes of 
transmission are mother-to-child, child-to-child, sexual and parenteral5. HBV is spread 
through contact with infected body fluids and the only natural host is human. Blood is the 
most important vehicle for transmission, but other body fluids have also been implicated, 
including semen and saliva. Currently, three modes of HBV transmission have been 
recognized; perinatal, sexual and parenteral / percutaneous transmission. There is no 
reliable evidence that airborne infections occur and feces are not a source of infection. 
HBV is not transmitted by contaminated food or water, insects or other vectors.5 
In the Middle East, there is limited information on sexual transmission in its societies.24In 
the United States; it is most commonly spread through sexual contact or injection drug 
use. Health care workers and others exposed to infected blood or body fluids are also at 
high risk for infection. However, approximately 30% of those infected have no known 
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risk factors. Worldwide, it is most commonly spread to infants by their infected 
mothers.25  
Sexual transmission remains the major mode of spread of HBV in developed countries. It 
is estimated that sexual transmission accounts for more than 50 percent of acute hepatitis 
B in the United States.26  
The incidence of transfusion-related hepatitis B decreased significantly after the 
exclusion of paid blood donors and the introduction of hepatitis B surface antigen 
(HBsAg) screening of donors. Patients requiring multiple transfusions, such as 
hemophiliacs and thalassemics, are at increased risk of contracting HBV 
infection26. A study of hepatitis B showed a prevalence of 12 % among blood 
donors in Sudan27. 
In the past, recipients of blood and blood products were at high risk (for HBV infection). 
Over the last 25 years, testing blood donations for HBsAg has become a universal 
requirement. Testing procedures have made major progress in sensitivity in the last 15-20 
years. However 19% of countries reported that they were not testing all blood donations 
for HBsAg (WHO Global Database on Blood Safety, unpublished data). In the many 
countries where pretransfusion screening of blood donations for HBsAg is carried out 
systematically, the residual risk of HBV transmission is minimal. Moreover, plasma 
derived medicinal products (including antihaemophilic factors) undergo additional viral 
inactivation and removal procedures resulting in greatly reduced or no transmission of 
HBV by these products. 28 
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Blood donors may not be representative of the general population. In some settings, blood 
donors tend to be healthier than individuals in the general population and consequently 
are more willing and capable of donating blood. In Saudi Arabia, blood donors appeared 
to have a lower prevalence of HBsAg (13.9%) when compared to the general population 
(16.7%) (P = 0.4). On the other hand, in countries where donors are paid for their blood, 
these individuals may have higher rates of infection than the general population. 
Additionally, blood donors who are relatives of patients suffering from chronic liver 
disease (CLD) and requiring blood transfusions may themselves have higher rates of viral 
hepatitis and liver disease than the general population. In the Republic of Yemen, it was 
found blood donors to have a significantly higher prevalence of HBsAg (20.6%) than 
non-donor apparently healthy individuals (12.1%) (P = 0.02). It is unclear whether these 
blood donors were paid or volunteer blood donors. Therefore, one cannot generalize 
findings based on studies conducted on blood donors.24 
Percutaneous transmission usually happens among intravenous drug users who share 
syringes and needles. Household contacts can also transmit hepatitis B through the 
sharing of razors or toothbrushes. Certain practices like acupuncture, tattooing, and body 
piercing have also been associated with transmission of hepatitis B.26 
The risk is still present in many developing countries. Contaminated and inadequately 
sterilized syringes and needles have resulted in outbreaks of hepatitis B among patients in 
clinics and physicians’ offices. Occasionally, outbreaks have been traced to tattoo parlors 
and acupuncturists. Rarely, transmission to patients from HBsAg positive health care 
workers has been documented. 28 
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In the Middle East, Parenteral transmission in health institutions should be limited due to 
routine screening of blood products. The number of intravenous drug users in the Middle 
East remains low compared to other regions, but there is little information on unsafe 
injection practices.24 
Transmission, in health care facilities, usually occurs from patient to patient or from 
patient to health care provider via contaminated instruments or accidental needle sticks. 
Healthcare workers, particularly surgeons, pathologists, and physicians working in hemo-
dialysis and oncology units, have the highest risks of HBV infection28. The prevalence of 
hepatitis B virus infection were estimated to be 6 % among health workers at Khartoum 
state .29 
 Children may acquire HBV infection through horizontal transmission via minor breaks 
in the skin or mucous membranes or close bodily contacts with other children. In 
addition, HBV can survive outside the human body for a prolonged period; as a result, 
transmission via contaminated household articles such as toothbrushes, razors, and even 
toys may be possible26. The prevalence of hepatitis BsAg was found to be 3.9% in 
children with sickle cell disease in some Khartoum hospitals .30 
Transmission of HBV from carrier mothers to their babies can occur during the perinatal 
period, and appears to be the most important factor in determining the prevalence of the 
infection in high endemicity areas, particularly in China and Southeast Asia. Before HBV 
vaccine was integrated into the routine immunization program, the proportion of babies 
that become HBV carriers is about 10-30% for mothers who are HBsAg-positive but 
HBeAg-negative. However, the incidence of perinatal infection is even greater, around 
70-90%, when the mother is both HBsAg-positive and HBeAg-positive. There are three 
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possible routes of transmission of HBV from infected mothers to infants: trans-placental 
transmission of HBV in utero; natal transmission during delivery; or postnatal 
transmission during care or through breast milk.5 
Among infants born to women in whom sera are positive for both the hepatitis B surface 
antigen and the e antigen, 85% to 90% are infected with hepatitis B virus and become 
chronic hepatitis B surface antigen carriers.31 
The infection rate among infants born to HBeAg-positive mothers is as high as 90 
percent. Maternal-infant transmission may occur in utero, at the time of birth, or after 
birth. The high protective efficacy of (95 percent) of neonatal vaccination suggests that 
infection occurs predominantly at or after birth.26There is no evidence that cesarean 
section prevents maternal-infant transmission. 26 Breast-feeding does not appear to 
increase the risk of transmission. 32Although HBV DNA has been detected in the 
colostrums of HBsAg positive mothers, a study on 147 infants born to carrier mothers 
revealed no evidence for a relationship between breast-feeding and the subsequent 
development of chronic HBV infection in the babies. 33 Transplacental passage of HBV is 
very rare. The risk of transmission during amniocentesis is also low, particularly in 
mothers who are HBeAg negative and when the procedure is done using a 22-gauge 
needle under continuous guidance transplacental passage of HBV is very rare. 26The high 
frequency of perinatal transmission in endemic areas is probably related to the high 
prevalence (40 to 50 percent) of HBeAg in women of reproductive age. These women 
remain infectious because of the slow rate of HBeAg seroconversion during the first two 
decades of life. Studies in Chinese children, for example, have found HBeAg in as many 
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as 90 percent below the age of 5, and up to 80 percent below the age of 20. The risk of 
maternal-infant transmission is related to the HBV replicative status of the mother. It is 
85 to 90 percent in infants born to HBeAg positive mothers and 32 percent in infants born 
to HBeAg negative mothers. A survey in an urban South-East Asia country estimated the 
overall risk of perinatal transmission in all HBsAg positive mothers to be 40 percent.32 
The high prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen 
(HBeAg) in pregnant women is considered to be the most important factor contributing to 
the high carrier rate of HBsAg in some populations. Several factors, including the age at 
which infection occurs, predispose to the acquisition and frequency of the carrier state. 
The proportion of infected people who become chronic carriers ranges from about 80 to 
95% for babies born to HBsAg/HBeAg-positive mothers.33 
Between 1977 and 1980, 1442 pregnant women in Thies, Senegal, were tested for 
serologic markers of hepatitis B virus (HBV) infection. Of these, 9.8% were HBsAg 
(+ve), Of 116 HBsAg (+ve) pregnant women, only 19.8% were HBeAg (+ve), a much 
lower proportion of infectious carriers than seen in Asian populations. Cord blood from 
1353 babies was HBsAg(-ve), implying that the babies were not infected prior to birth. 
Four hundred sixty-two babies, including 88 born to HBsAg (+ve) mothers, were 
observed for 2 weeks to 38 months after birth. In contrast to observations in Asia, none of 
the babies became HBsAg(+ve) before 5 months of age, and only three of the 16 born to 
HBeAg(+ve) mothers became HBsAg(+ve) within the first year of life; all three 
developed chronic infections (i.e., HBsAg(+) for greater than or equal to 6 months. In the 
second year of life, six of 34 babies born to HBsAg(+ve), HBeAg(-ve)/anti-HBe(-ve) 
mothers became infected with HBV, and four of the six developed chronic infections. 
   
  18 
 
During the first 3 years of life, infections occurred at a higher rate in infants born to 
HBsAg(+ve) (17%) than to HBsAg(-) (4%) women. The latter group of infants included 
4.0% of those born to anti-HBsAg (+ve) mothers, 4.6% born to anti-HBcAg(+ve), and 
3.2% born to uninfected women. These observations indicate that HBV infection in 
Senegal usually do not occurs perinataly, but do occur at high incidence later in infancy 
and childhood. Such infections can be prevented by the use of hepatitis B vaccine alone; 
administration of hepatitis B immune globulin should not be needed.34 
A total of 7.1% of the women in Oman, 1% in Qatar and 1.5% in UAE were HBsAg-
positive. Three (0.5%) women in Oman were HBeAg-positive.35 Risk factors identified 
for being HBsAg-positive were younger age, being a national (i.e. not an expatriate) and 
residing outside the city. Results from this study have shown that hepatitis B virus (HBV) 
prevalence in pregnant women is of intermediate endemicity in Oman and of low 
endemicity in Qatar and UAE. Thus, universal vaccination of all female adolescents 
before potential pregnancy is recommended in Oman in order to prevent perinatal 
infection, as well as to minimize horizontal transmission of the HBV in the community.35 
In the Middle East, the majority of infections occur through childhood and perinatal 
transmission. Studies on the magnitude of perinatal and childhood transmission in the 
Middle East have produced differing results. While some studies suggest that childhood 
transmission is the major mode of transmission of HBV infection with perinatal 
transmission being uncommon, others propose that perinatal transmission plays an 
important role in contributing to the pool of chronic carriers. Considering the 
heterogeneity of Middle East populations and the difference in the prevalence of chronic 
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carriers and HBeAg positivity amongst women of childbearing age within them, 
intercountry differences in the mode of transmission probably exist. 
Supporting the role of childhood transmission in the Middle East, person-to-person, non-
sexual, non-parenteral and intra-familial contact was the major mode of transmission 
between asymptomatic HBV carriers and susceptible individuals.24 A combined study in 
four Middle East countries found that only 21% (25/120) of children born to HBsAg-
positive mothers became chronic carriers. This was attributed to the low prevalence of 
HBeAg (13%) amongst HBsAg-positive mothers, although 94% (15/16) of HBeAg-
positive mothers transmitted HBV to their infants.24 
A study in Kuwait found the prevalence of HBsAg among pregnant women to be 2.9% 
(45/1554), 7.3% of whom were positive for HBeAg. Based on the low prevalence of 
HBeAg amongst pregnant women, they predicted a low transmission rate of infection to 
offspring.24 In Lebanon, similar prevalence rates of HBsAg (2.9%) (16/558) and HBeAg 
(6.3%) was found amongst pregnant women and accordingly one would expect a low 
mother-to-child transmission as in Kuwait.24 
A study in the Jizan area in Saudi Arabia, suggested that perinatal transmission was 
unlikely to play an important role in HBV hyper-endemicity in Jizan due to the low 
HBeAg positivity of 9% (6/67) in carrier males and females alike associated with a low 
prevalence of HBsAg in females of childbearing age (4.9%).24 
Another study conducted on mother-to-child transmission of HBV in Saudi Arabia, found 
2.8% (140/5000) of pregnant women positive for HBsAg. A two-year follow-up of 50 
HBsAg-positive women, 12% of whom (6/50) were positive for HBeAg and their 
neonates showed that none of the children became HBsAg-positive . A similar study by 
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Ramia et al. conducted on 3020 women showed the overall prevalence of HBsAg to be 
3.9% amongst pregnant women in Saudi, 11% of whom (13/119) were positive for 
HBeAg.24 Another study by the same authors looking into transplacental transmission of 
HBV infection by HBsAg carrier mothers suggested a lack of evidence for perinatal 
transmission .24 
On the other hand, there are studies supporting the role of perinatal transmission of HBV 
infection in the Middle East. Due to a high rate of HBsAg (9.7%) amongst children aged 
1 year in Saudi Arabia, suggested the possibility of significant HBV transmission during 
the perinatal period or soon after.26 In the Republic of Yemen, approximately 17% 
(40/243) of pregnant women were HBsAg positive and 32% (9/28) of HBsAg-positive 
pregnant women were HBeAg-positive. This high prevalence of HBeAg in pregnant 
Yemeni women indicates a potentially high rate of perinatal transmission of HBV.25 
Another small study suggested the rate of mother-to-child transmission to be 50% (10/20) 
from HBsAg-positive mothers, based on cord blood positive for HBsAg .24 
Studies in Egypt also suggest that perinatal transmission is relatively high. A study has 
detected HBsAg in 8% (12/150) among pregnant mothers and 17% (2/12) of their infants. 
None of the HBsAg-positive mothers or their infants was HBeAg positive. In another 
study conducted in Egypt, 17% (6/35) of infants born to HBsAg-positive mothers were 
HBeAg-positive, and HBsAg was positive in 25%, 22% and 37% of cord, 3-month and 6-
month blood specimens respectively. Out of 6 babies who became infected from HBeAg-
positive mothers, 5 (83%) showed infection at 3 months and 1 did not show infection 
until 6 months.24 
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Mother to child transmission was studied in juba , southern Sudan , on 88 mother child 
pairs (mean age 15.5 months) where on 9 HBsAg positive mothers , five of their children 
were also HBsAg positive (55.5%)whereas on 79 HBsAg negative mothers only 9 
children became HBsAg positive .36 
A large study in the Gezira area showed that 70% of the HBsAg positive women of child 
bearing age were HBeAg positive , indicating that maternal-infant transmission might be 
an important risk factor in this part of the country.36 
In Khartoum state, the seroprevealance of HBsAg in pregnant women was found to be 
16.4% in a study carried out at an antenatal clinic36. Another cross sectional hospital 
based study was conducted, in Omdurman Maternity Hospital, among 391 randomly 
selected delivering women and 353 newborn for the women found that HBsAg was 4.1% 
among the women and 1.52% among the neonates .37 
In developed countries like United States to identify newborns who require 
immunoprophylaxis to prevent perinatal HBV infection, all vaccine advisory groups have 
recommended routine HBsAg screening of all pregnant women during an early prenatal 
visit in each pregnancy.38Federal funding to support perinatal hepatitis B-prevention 
programs became available in 1990, and by 1992, programs had been implemented in all 
50 states and the District of Columbia. Specific objectives of these programs are to ensure 
that all pregnant women are tested for HBsAg, and infants born to HBsAg-positive 
women receive hepatitis B immune globulin (HBIG) and hepatitis B vaccine at birth, 
with follow-up doses of vaccine at ages 1 and 6 months. This describes the case-
management features of successful hepatitis B-prevention programs in Connecticut 
during 1994-95 and in the United States during 1994. Connecticut .38 In many previous 
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studies in countries with low endemicity, such as Britain and North America, have looked 
at selective versus universal antenatal screening. When a direct comparison has been 
made, selective screening failed to identify about half of the women whose babies were at 
risk. Among the reasons for the failure of selective systems are the difficulties of 
discussing risk behaviors in a busy antenatal clinic, the possibility that women with no 
risk factors might have been infected by a partner with a "risk history," and many infected 
women have no recognized risk factors. As a result of the study in the Netherlands the 
Dutch national health authority has adopted as policy non-selective screening for hepatitis 
B infection. 38 
The main risk factors for hepatitis B are Engaging in unsafe sex, particularly unprotected 
receptive anal sex, having sex with more than one partner or with a partner who has or 
has had more than one partner or who uses or has used IV drugs, sharing needles, 
IVdrugs, and drug , Recent history of STI infection, having a blood transfusion or 
treatment with infected blood products, getting a tattoo or piercing, having a job (such as 
a health care worker) that exposes one to blood or other body fluids, traveling or living in 
areas with high rates of HBV infection (including Southeast Asia, the Amazon basin in 
South America, the Pacific Islands, the Middle East).6 
The incidence of HBV infection differs significantly by race and ethnicity with the 
highest rates among blacks; rates are higher among Hispanics than non-Hispanics. 
Incidence also varies by age with the highest rates reported among persons 20-39 years of 
age. Less than 5% of the HBV infections that occur among children are reported as cases 
of acute hepatitis B to CDC because HBV infections that occur in infants and children 
rarely produce signs or symptoms of disease. Furthermore, chronic HBV infection 
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develops in approximately 90% of children infected at birth and 30%-60% of children 
infected between 1 to 5 years of age compared with 2%-6% of older children and adults; 
thus, prior to routine immunoprophylaxis of infants and children, cases occurring in 
children accounted for a disproportionate amount of the disease burden due to chronic 
infection.39 
A study was conducted in the United States to estimate race/ethnicity-specific prevalence 
of hepatitis B surface antigen (HBsAg) in pregnant urban women and to evaluate factors 
associated with maternal HBsAg testing , showed that HBsAg prevalence among white 
non-Hispanics was 0.60% (95% confidence interval [CI]: 0.22–0.98), black non-
Hispanics 0.97% (95% CI: 0.48–1.47), Hispanics 0.14% (95% CI: 0.01–0.26), and Asians 
5.79% (95% CI: 4.42–7.16). HBsAg testing rates increased from 56.6% in 1990 to 78.2% 
in 1993.40 
The risk of chronic infection decreases with age when the infection has been aquired41. 
The earlier the disease is acquired, the greater the chance of developing chronic infection. 
Infants (mainly infected through vertical transmission) have a 90% chance, children have 
a 25-50% chance, adults have an approximately 5% chance, and persons who are elderly 
have an approximately 20-30% chance of developing chronic disease.17 
A model was developed to calculate the age-specific risk of acquiring HBV infection, 
acute hepatitis B (illness and death), and progression to chronic HBV infection. HBV-
related deaths among chronically infected persons were determined from HBV-related 
cirrhosis and hepatocellular carcinoma (HCC) mortality curves, adjusted for background 
mortality. The effect of hepatitis B vaccination was calculated from vaccine efficacy and 
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vaccination series coverage, with and without administration of the first dose of vaccine 
within 24 h of birth (i.e. birth dose) to prevent perinatal HBV infection. RESULTS: For 
the year 2000, the model estimated 620 000 persons died worldwide from HBV-related 
causes: 580 000 (94%) from chronic infection-related cirrhosis and HCC and 40 000 
(6%) from acute hepatitis B. In the surviving birth cohort for the year 2000, the model 
estimated that without vaccination, 64.8 million would become HBV-infected and 1.4 
million would die from HBV-related disease. Infections acquired during the perinatal 
period, in early childhood (<5 years old), and >/=5 years of age accounted for 21, 48, and 
31% of deaths, respectively. Routine infant hepatitis B vaccination, with 90% coverage 
and the first dose administered at birth would prevent 84% of global HBV-related deaths. 
Globally, most HBV-related deaths result from the chronic sequel of infection acquired in 
the perinatal and early childhood periods. Inclusion of hepatitis B vaccine into national 
infant immunization programs could prevent >80% of HBV-related deaths.42 
This study identifies the risk factors for hepatitis B virus (HBV) and hepatitis C virus 
(HCV) and measures the prevalence of hepatitis B surface antigen (HBsAg) and antibody 
to hepatitis C (anti-HCV) in the general population of Jakarta. A population-based sample 
of 985 people aged 15 and above was surveyed. Risk factors were identified through 
questionnaires and home visits. Serum was analyzed for HBsAg, antibody to hepatitis B 
surface antigen (anti-HBs), anti-HCV, aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). The seroprevalence was: 4.0% (39/985) for HBsAg, 17.2% 
(170/985) for anti-HBs, and 3.9% (38/985) for anti-HCV. The risk factors for hepatitis B 
and hepatitis C infection had little in common. Low socioeconomic status was a strong 
risk factor for HBsAg (adjusted odds ratio (OR) 18.09; 95% confidence interval (CI) 
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2.35-139.50). In addition, the Chinese group has 2.97 higher risk of having HBV 
infection compared with the Malayan ethnic group (adjusted OR 2.97; 95% CI 1.22-
7.83). There was moderate positive trend between family size and risk of HBsAg 
positivity (P = 0.130). Age over 50 (adjusted OR 14.72; 95% CI 4.35-49.89) and history 
of transfusion were significant risk factors for hepatitis C (adjusted OR 3.03; 95% CI 
1.25-7.33). Hepatitis B and hepatitis C infections have different risk factors in Jakarta, a 
high risk in population for both diseases. Hepatitis B transmission is associated with low 
socioeconomic status, Chinese ethnic group and large family size, while hepatitis C is 
associated with an older age and a history of transfusions.43 
The most common factors found to be associated with HBV infection and carrier status in 
the Middle East, other than the risk of perinatal transmission associated with 
HBsAg/HBeAg status of the mother, are family size, socioeconomic status, age, 
educational status and a history of previous blood transfusion, surgery or contact with a 
jaundiced person.24 
Most HBV infections in developed countries result from sexual activity, injection-drug 
use, or occupational exposure. Other, less frequent causes of infection include household 
contact, hemodialysis, transmission from a surgeon, and receipt of organs or blood 
products. No clear risk factors are found in 20 to 30 percent of patients, perhaps because 
of a reluctance to report high-risk behavior or possibly mucosal or other unrecognized 
routes of infection.12 
Evidence supporting the role of large family size in increasing the risk of HBV infection 
came from the observation of pronounced familial clustering of HBV infection in Jordan. 
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A significant correlation was found between family size and the proportion of HBsAg-
positive family members. Also in Jordan, there was a significantly greater HBsAg 
prevalence in lower (14.4%) than in upper (2.4%) socioeconomic classes. Another study 
supporting this evidence showed the prevalence of HBsAg to be 11% and 4% 
respectively amongst low and high socioeconomic classes. Earlier studies have also 
shown the prevalence of HBsAg to be 6.9% and 0.7% respectively in lower and upper 
socioeconomic classes. Similar findings have been reported from the Syrian Arab 
Republic and Egypt, where the risk of infection was found to be greater in children of low 
compared to children of high socioeconomic status.24 The association of a history of 
jaundice, previous blood transfusions and surgery with HBV infection and carrier status 
has been reported in Jordan, Egypt and the Republic of Yemen. In the Republic of 
Yemen, a multivariate analysis found age, a history of jaundice and a combined history of 
blood transfusion and surgery to be associated with HBV infection. The odds ratio 
associated with increasing 10-year age intervals was 1.37 and 1.51 for carrier status and 
total markers respectively. 24 The adjusted odds ratio for a combined history of surgery 
and blood transfusion was 2.76 (95% CI: 1.11–6.82). The adjusted odds ratio for a history 
of jaundice was 1.42 (95% CI: 1.01–2.01). 24 Toukan et al. reported similar findings in 
Jordan [18]. In addition, they also found past or present HBV infection to be associated 
with a rural background, injections, tattooing, sexual exposure and surgical procedures. 
24In Egypt, Ghaffar et al. examined risk factors for perinatal transmission. Apart from the 
proven importance of HBeAg/anti-HBe status in perinatal transmission, they found that 
maternal history of schistosomal infection was significantly associated with perinatal 
transmission. 24 A possible explanation for this association was that schistosomal 
   
  27 
 
infection resulted in impaired cell-mediated immunity(indicator of low socio-economic 
status ) and hence increased viraemia and infectivity. They also found higher rates of 
HBV transmission in rural areas as well as in mothers with low educational status. 24 A 
negative correlation between prevalence of HBV infection and educational levels has also 
been observed in the Islamic Republic of Iran. 24 
History of jaundice, contact with jaundiced patient, blood transfusion past history of 
operation ,tattooing contact with blood was found statistically insignificant in a study 
conducted among pregnant women in Omdurman maternity hospitals .37 
Study conducted among children of sickle cell anemia in pediatrics hospitals in 
Khartoum, found that there is no significant relation between HBV prevalence and blood 
transfusion, tribal markers, surgery, parents’ education and mother occupation .30 
Hepatitis B Immune Globulin (HBIG) is a sterile solution of ready-made antibodies 
against hepatitis B. HBIG is prepared from human blood from selected donors who 
already have a high level of antibodies to hepatitis B and used in passive 
immunoprophylaxis. Passive immunoprophylaxis is used in four situations; newborns of 
mothers infected with hepatitis B, after needle stick exposure, after sexual exposure, and 
after liver transplantation. 
 Immunoprophylaxis is recommended for all infants born to HBsAg positive mothers. 
Current dosing recommendations are 0.13ml/kg HBIG immediately after delivery or 
within 12 hours after birth in combination with recombinant vaccine. The combination 
results in a higher-than-90% level of protection against perinatal acquisition of HBV.44 
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About 3.7% to 9.9% of infants still acquire HBV perinatal infection from HBV-infection 
mothers, despite immuno-prophylaxis. Failure of passive and active immuno-prophylaxis 
in this setting may be the result of in utero transmission of HBV infection, perinatal 
transmission related to a high inoculum, and/or the presence of surface gene escape 
mutants.44 To study the interruptive effect of HBIG before delivery in attempt to prevent 
intrauterine transmission of HBV, a large-scale, random-control study was conducted in 
China . In this study, nine hundred and eighty HBsAg carrier pregnant women were 
randomly divided into HBIG group and control group. Each subject in the HBIG group 
received 200 IU or 400 IU of HBIG intramuscularly at 3, 2 and 1 month before delivery, 
in addition to newborns receiving HBIG intramuscularly. By this way, the rate of 
intrauterine transmission in this group fall to 5.7%, compared to 14.3% in control group. 
(P < 0.001). However, the preventive effect of HBIG administration before delivery 
needs to be confirmed by more study in the future. 5 
Hepatitis B immune globulin remains a central component of prophylaxis in HBV-
infected patients undergoing liver transplantation. HBIG monotherapy given at a high 
dosage can prevent recurrence in 65% to 80% of patients. Because the cost of long-term 
prophylaxis with high-dose HBIG is extremely high and combination therapy using 
HBIG with a nucleoside analog is more uniformly effective, the current protocol is 
combination HBIG with a nucleoside analog after liver transplantation. These 
combination protocols have reduced the rate of virologic breakthrough to 10% or less .5 
Prevention of primary infection by vaccination is an important strategy to decrease the 
risk of chronic HBV infection and its subsequent complications. The first-generation 
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hepatitis B vaccine, an inactive plasma-derived vaccine, became available in 1982;7 
consequently; the second generation of HB vaccine, a DNA recombinant HB vaccine was 
also available for general use in 1986. Both of the vaccines were proven to be safe and 
efficacious in preventing HBV infection. In 1991, the World Health Organization (WHO) 
recommended that hepatitis B vaccination should be included in national immunization 
system in all countries with a hepatitis B carrier prevalence (HBsAg) of 8% or greater by 
1995 and in all countries by 1997. By May 2002, 154 countries had routine infant 
immunization with hepatitis B vaccine .7 
Vaccines are given in three doses (at 0, 1, and 6 months) of 10-30 µg (usually 20 µg for 
adults and 10 µg for children). The vaccines are extremely safe and induce antibodies that 
will neutralize HBsAg (anti-HBsAg) in most (> 95%) recipients; antibody levels in 
excess of 10 U/ml are considered protective. Certain groups—people aged over 40, obese 
people, those with chronic renal failure, haemo-dialysis recipients, immuno-suppressed 
individuals, organ transplant recipients—have poorer response rates. The protection lasts 
for at least 15 years, and because of strong immunological memory it continues after anti-
HBs have become undetectable. Immunity is thus believed to be life long, and boosters 
are not recommended routinely; however, these may have a role in immuno-suppressed 
individuals and those at a particularly high risk of exposure. Non-responders to three 
doses may benefit from additional doses of the vaccine. 44 
Regarding immunogenicity in Neonates, it was found that immunization with 10 mcg at 
0, 1, and 6 months of age produced seroconversion in 100% of infants by month 7, with a 
geometric mean antibody titer (GMT) of 713 IU/ml (N = 52), and the seroprotection rate 
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was 97%. 3 Clinical trials indicate that administration of hepatitis B immune globulin at 
birth does not alter the response to ENGERIX-B.40 
Immunization with 10 mcg at 0, 1, and 2 months of age produced a seroprotection rate of 
96% in infants by month 4, with a GMT among seroconverters of 210 IU/ml (N = 311); 
an additional dose at month 12 produced a GMT among seroconverters of 2,941 IU/ml at 
month 13 (N = 126).45 
As Immunogenicity in Pediatric Patients is concerned; clinical trials in 242 children aged 
6 months to, and including, 10 years given 10 mcg at months 0, 1, and 6, the 
seroprotection rate was 98% 1 to 2 months after the third dose; the GMT of 
seroconverters was 4,023 IU/ml. In a separate clinical trial including both children and 
adolescents aged 5 to 16 years, 10 mcg of ENGERIX-B was administered at 0, 1, and 6 
months (N = 181) or 0, 12, and 24 months (N = 161). Immediately before the third dose 
of vaccine, seroprotection was achieved in 92.3% of subjects vaccinated on the 0-, 1-, and 
6-month schedule and 88.8% of subjects on the 0, 12, and 24 month schedule (117.9 
IU/ml versus 162.1 IU/ml, respectively, p = 0.18).46One month following the third dose, 
seroprotection was achieved in 99.5% of children vaccinated on the 0-, 1-, and 6-month 
schedule compared to 98.1% of those on the 0-, 12-, and 24-month schedule. GMTs were 
higher (p = 0.02) for children receiving vaccine on the 0-, 1-, and 6-month schedule 
compared to those on the 0-, 12-, and 24-month schedule (5,687.4 IU/ml versus 3,158.7 
IU/ml, respectively). The clinical relevance of this finding is unknown.47The 
recommended series of three intramuscular doses of hepatitis B vaccine induces a 
protective antibody response (anti-HBsAg >=10 IU/ml) in >90% of healthy adults and in 
>95% of infants, children, and adolescents. Hepatitis B vaccine should be administered 
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only in the deltoid muscle of adults and children or in the antero-lateral thigh muscle of 
neonates and infants; the immunogenicity of the vaccine for adults is substantially lower 
when injections are administered in the buttock.34 When hepatitis B vaccine is 
administered to infants at the same time as other vaccines, separate sites in the 
anterolateral thigh may be used for the multiple injections. This method is preferable to 
administering vaccine at sites such as the buttock or deltoid.46 
A total of 110 high-risk infants born to women who were carriers of HBsAg positive for 
HBeAg were randomized into two groups. The first group (54 infants) received a 20-
[microgram] dose of surface antigen at birth and at one month, two months and 12 
months of age. The second group (56 infants) received a 10-[microgram] dose of surface 
antigent at the same time periods. Another group of 60 high-risk infants who were 
recruited later received a 20-[microgram] dose of vaccine at birth and at one month and 
six months of age. All of the infants received a dose of hepatitis B immunoglobulin 
intramuscularly within 24 hours of birth.47 No statistically significant differences were 
found among the infants in the three groups. The vaccine was more than 90 percent 
effective in each of the three dosage regimens and in combination with hepatitis B 
immunoglobin. The infants who received the 20-[microgram] doses had higher antibody 
titer than the infants who received the 10-[microgram] doses, but the clinical significance 
of this phenomenon is not known. Adverse reactions were rare and mild.47 
Hepatitis B vaccination has been shown to reduce the prevalence of chronic HBV 
infection and the incidence of HCC dramatically. In The Gambia, the prevalence of 
chronic infection among children declined from 10.0% to 0.6% after implementation of 
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universal infant hepatitis B vaccination. Similar declines in prevalence of chronic 
infection associated with infant and childhood hepatitis B vaccination have been 
demonstrated in China, Indonesia, Senegal, and Thailand, and among Alaska Natives. 
After implementation of universal infant hepatitis B vaccination in Taiwan, the incidence 
of HCC among children declined from 0.7 to 0.36 per 100,000.46 
A major barrier to the introduction of hepatitis B vaccination has been the high cost of 
hepatitis B vaccines. Although the price of monovalent hepatitis B vaccine for developing 
countries has decreased from approximately U.S.$3.00 per dose in 1990 to U.S.$0.30 per 
dose in 2001, the cost remains higher than that of the older vaccines (e.g., DTP, oral 
polio, and measles), which cost U.S.$0.06--$0.10 per dose. Since 1999, support from the 
Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund (VF) has 
accelerated introduction of hepatitis B vaccine in the world's poorest countries. As of 
May 2003, of 75 countries eligible for GAVI/VF support, 48 (64%) had received funding 
for hepatitis B vaccination introduction.47 
Administration of a birth dose of vaccine presents a challenge. Worldwide, approximately 
50% of infants are born at home and do not have immediate access to health care. 
However, because hepatitis B vaccine has been shown to be heat stable, it could be 
administered by trained birth attendants to infants born at home. The feasibility of such a 
strategy has been demonstrated in Indonesia, where trained birth attendants were taught 
to administer the birth dose of vaccine to infants born at home by using a single-use, pre-
filled injection device.48 
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Study design: 
Descriptive cross-sectional - health facility based study.  
Study area: 
Khartoum state is one of the 26 states of Sudan. It is the capital of Sudan. It has political 
and commercial importance. Not only because it is the capital but also because of its 
location. It is situated in the centre of Sudan.  Area is 2, 0140 Km2. The state has been 
divided into seven localities. Number of health centers in Khartoum State is 143, 
distributed all over the localities.49  
About 44% of the population of the state is lifetime migrants. A study conducted by the 
National Population Council showed that approximately 1,000 persons enter and settle in 
the state daily.49 
Sex ratio in the state was found to be 410 males per 1000 population. Average size of the 
households is 6.1 persons per house. Children under five accounts for 15.1 % (higher in 
the rural areas), while those under 14 years of age constitute 37.6%. The working age 
(15-59) accounts for 57.9% of the total population. 
Religions: Muslim 70%, indigenous beliefs 25%, Christians 5%. 49 
Study population: 
All pregnant women attending ANC unit in Khartoum State. 
Inclusion criteria: 
1/ Pregnant women attending ANC units for antenatal care visits. 
2/ Women accept to be involved in the study. 
3/ Any age.        
4/  Any gestational age. 
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Sampling  
Sample design:  
Two stage cluster sample with stratification technique was followed. All 7 
localities in Khartoum State (Khartoum, Jabal Awlia, Bahry, Sharq Alniel, 
Omdurman, Karary, and Umbada) were taken in the sample. Annex IV  
In stage 1, a total of 20 ANC centers were selected by stratification from 
governmental, NGOs centers, Federal and State hospitals proportional to the 
number of health facilities that provide ANC services among different types. This 
resulted in selection of 6, 10, 2, and 2 centers from each stratum respectively, and 
then the number of ANC centers selected from each locality is taken according to 
the frequency of women attending the ANC centers (Annex IV).50 The nearest 
true number was taken in Proportions with fractions. ANC units were selected 
randomly from the list in each locality using random digit table.  
In stage 2 the calculated sample size of women, 314, was divided proportional to 
size among the selected ANC centers. In the selected centers women were chosen 
randomly from the registration book using the random digit table. Where the 
sample size was exceeding the registered number, all women registered in the day 
of visit, were selected and the sample was completed in the next days.  
Sample size:   
A/sample of 20antenatal care unit was taken. 
B/ sample of 314 pregnant woman was taken using the following formula: 
n = z2 (pq) *design effect 
         d2  
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z = Confidence level = 1.96 corresponds to 95 % in Z table 
p  =  prevalence=0.08   , q  =  1-p=0.92 , d2 = desired margin of error = 0.03 
Design effect (design will be over weight by stratification) =1.8 
n = 314 
 
Data collectors:  
Twelve data collectors had participated in the process of data collection, 
divided equally among 3 teams, each one composed of 2 data collectors, lab 
technician and field supervisor. They had received 2 days training on the 
filling of the questionnaire and collection of blood samples. This was followed 
by pre testing of the questionnaire in the unselected centers.    
Tools for data collection: 
A pre designed questionnaire was used (annex I), which showed the following variables; 
age, tribe, marital status, number of children, type and place of delivery, level of 
education for the woman and husband, occupation of the woman and husband, history of 
blood transfusion for the woman and husband, history of unsafe injection to the woman 
and husband, past history of jaundice and renal dialysis for both woman and husband, 
number of other wives, vaccination history with HBV vaccine and previous testing for 
HBV.   
 Blood samples were taken from each woman before filling the questionnaire. Each 
woman was given a code, which was the same for the questionnaire and the blood sample 
container. 5 ml of intravenous blood was taken using a tourniquet and alcohol for local 
disinfection. The blood containers were taken by the end of the day to the lab, in sample 
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carriers, where they were centrifuged and kept in fridges at -8 C0. Laboratory tests were 
performed at Khartoum State - ministry of health’s lab. Blood samples were screened for 
hepatitis B virus’s s and e antigens using the ELISA Test. Results were considered as 
positive for HBsAg after being reexamined with the ELISA test.  
Ethical considerations: 
? Ethical clearance certificate has been obtained from the ethical committee of the 
Federal Ministry of Health (annex III). 
? Women had given a written consent before taking the blood samples following 
explanation of the procedure and its purpose.(Annex II) 
? Women with positive results were informed through phone to take safety 
precautions and to ask for the vaccine and immunoglobulin for her child 
immediately after birth. 
? Blood was collected by lab technician who were trained on safety of injection 




Data were analyzed using Spss-13 soft ware program. Prevalence of HBsAg and HBeAg 
was calculated with 95% confidence interval and the risk of perinatal HBV transmission 
was measured by the frequency of    HBsAg /HBeAg positive women .10Then HBsAg 
prevalence by age and other risk factors was calculated using odds ratio and logistic 
regression.   
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Three hundred and twenty pregnant women were tested for hepatitis B surface antigen. 
The main results obtained for this study are shown in (table 1), where (12/320) 3.75% 
(95% CI: 3.77-3.73) women were tested positive for HBsAg and only one woman out of 
the12 {8.33% (95% CI:8,49-8.17)} was hepatitis B e antigen positive. Prevalence of 
HBsAg & HBeAg positive mothers is 0.31%, Frequency of HBV carriers in population 
due to perinatal infection is 0.25%.  
Fifty two percent (166/320) of these women were from Omdurman locality and 
11%(35/320) women were from Jabal Awlia ,10%(32/320) were from Khartoum locality, 
8%(26/320) from Khartoum North (Bahry), 8%(26/320)  woman were from Umbada 
locality, 8%(26/320) were from Sharg Alnil and 3%(10/320) were from Kararry locality 
.(Figure 1 ). 
Fifty two percent (166/320) women were from hospitals, 23% (74/320)were from 
governmental health facilities ,and 24%(77/320) women were selected from   non 
governmental organization health facilities.(figure No.2) 
Fifty eight percent (185/320) of the study population were from southern Sudan and 42% 
(134/320) women were from northern Sudan. (Figure No.3) Six foreigner women were  
included in the study, two from Syria, one from Chad, one from Ethiopia, one from 
turkey and one woman is from Cameron. 
The number of women aged less than 20 years of age were 10 %( 32/320), women aged 
between 20 to 29 years were 52 %( 164/320) and those who age 30 and above were 
(120/320) with median age of 27 years (figure No.4).  
Figure No. 5 shows that 48 %( 154/320) women involved in the study received less   than 
9 years of education, and 52% (166/320) get more than 9 years of education.  
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Forty five percent (144/320) of the husbands received less   than 9 years of education, and 
55 %( 176/320) get more than 9 years of education (figure No, 6). 
Ninety seven percent (310/320) of the study population had non risky occupation, 3 % (9 
/320) were health workers (risky occupation (figure No.7). 
Twenty percent (64/320) of the husbands had a risky occupation (militaries, truck drivers 
and health workers), and 80 %( 256/320) of the husbands were having a non risky jobs 
(Figure No.8). 
Twenty eight percent (90/320) of the study population having a more than 3 children, and 
72% (230/320) have less than 3 children (figure No.9).  
Three hundred and nineteen women included in the study were married (99.7%).and the 
one woman is divorced (0.3%). 
Seventy seven percent (170/220) of the study population having children were delivered 
vaginally, 13% (28/220) by caesarean section and 10% (22/220) by both vaginal and 
caesarean section (figure No. 10). 
Twenty five percent (81/220) of those who delivered before were delivered at home, and 
63% (139/220) women delivered at hospital (figure No.11). 
Sixteen percent (52/320) of the husbands have other wives and 83.7 % (268/320) didn’t 
have (Figure No. 12)  
Fifty six percent (29/52) of those husbands who have other wives have one more wife, 35 
%( 18/52) have two more wives and 9 %( 5/52) husbands have three more wives (figure 
No.13). 
Three hundred and eighteen (99.4%) of the pregnant women in Khartoum state didn’t 
vaccinate before, and2 (0.6%) vaccinated. 
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Table 2 shows that There was insignificant relation (p>0.05) between HBsAg prevalence 
and risk factors (age, African racial roots, education, husband’s education, Risky 
occupations, Family size, Husbands having other wives, Blood transfusion, Blood 
transfusion for husbands, Unsafe injection, History of jaundice, Husband’s history of 
jaundice). 
 The odds ratio for age was 0.644(95%CI:0.164-2.527), The odds ratio for African racial 
roots was 0.514(95%CI:0.139-1.905), The odds ratio for education less than 9 years 
was1.139 (95%CI:0.272-4.774), The odds ratio for husbands  education less than 9 years 
was1.159(95%CI:0.29-4.63), The odds ratio for Risky occupations was 1.91 
(95%CI:0.000-2.24), The odds ratio for Husband’s risky occupation 
was0.461(95%CI:0.166-1.82), The odds ratio for Family size was2.20(95%CI:0.356-
13.61), The odds ratio for Husbands having other wives was2.06(95%CI:.0.356-13.61), 
The odds ratio for history of Blood transfusion was1.85(95%CI:..0180-18.96), The odds 
ratio for husband history of Blood transfusion was 0.360(95%CI:..0.034-3.77), The odds 
ratio for Unsafe injection was 0.592(95%CI: 0.046-7.70), The odds ratio for History of 
jaundice was0.735 (95%CI:0.175-3.095), The odds ratio for Husband’s History of  
jaundice was2.014 (95%CI: 0.240-16.870). No relation was detected between hepatitis B 
infection and husband's history of unsafe injection, and history of renal dialysis for both 









Table No. 1 Prevalence of hepatitis Bs and e among pregnant 
women and estimates of frequency of perinatal HBV 
transmission Khartoum State 2005-2006 
 
%  Calculation(No.)  
   
  
Measures  
3.75% (95% CI:3.77-3.73)   12/320  HBsAg prevalence  
 
8.33% (95% CI:8,49-8.17)  1/12  HBeAg prevalence 
0.31%  0.0375X 0.0833 prevalence of HBsAg & HBeAg positive mothers 
0.25%***  0.311% X 0.8**  Frequency of HBV carriers in population due to 
perinatal infection  
 
*Moderate endemicity.  
**Efficiency of perinatal transmission10 
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Figure No.2 distribution of study population 
among different types of health facilities
N=320
Types of health facilities































Figure No.3 distribution of the 
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Figure No.4 Distribution of study population
according to the age groups
N =320
Age groups
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Figure N0.5 Distribution of study population 
according to the years of systematic education
N= 320 
Years of systematic education
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Figure N0.6 distribution of study population
according to the years of husband systematic  education
N= 320
Years of husband education






















































1. Health worker. 
2. Truck driver. 










Figure No.8 distribution of study population
according to husbands occupation
N= 320
Husband occupation































Figure No.9 Classification of study population
according to the number of children 
N = 320
Number of children




























Figure No.10 Classification of study population

























Figure No.11 classification of study population




























Figure No.12 distribution of study population
according to husband being married to other wives
N=320
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Figure No.13 distribution of study population
according to the number of other wives
N= 52
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            Table No. 2:  
             Relation of HBV risk factors with HBsAg positive study population using logistic regression  
 
• All factors are statistically insignificant  
95.0% Confidence 
interval for Odds ratio 
Risk factor Frequency  Percentage Odds ratio 
Lower Upper 
P value 
Age less than 27  years 162 50.62 % 0.644 0.164 2.527 0.528 
African racial roots 133 41.56 % 0.514 0.139 1.905 0.319 
Less than 9 years of education  155 48.44 % 1.139 0.272 4.774 0.859 
Less than 9 years of  husband’s education 144 45.00 % 1.159 0.290 4.638 0.835 
Risky occupation 9 02.81 % 1.080 0.419 2.786 0.873 
Husband's Risky occupation 63 19.69 % 0.461 0.116 1.829 0.271 
Family size 91 28.44 % 2.202 0.356 13.610 0.396 
Husbands having other wives 52 16.25 % 2.066 0.230 18.556 0.517 
Blood transfusion  30 10.00 % 1.850 0.180 18.962 0.604 
Blood transfusion for husbands 11 03.44 % 0.360 0.034 3.772 0.394 
Unsafe injection  13 04.06 % 0.592 0.046 7.700 0.689 
History of jaundice 78 24.38 % 0.735 0.175 3.095 0.675 
Husband’s history of jaundice  54 16.88 % 2.014 0.240 16.870 0.518 
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The aim of this study was to estimate the prevalence of HBV among pregnant women in 
Khartoum State.  The results of  this study revealed that, the number of pregnant women 
with hepatitis B surface antigen positive was found to be 3.75% (95% CI:3.7- 3.8). 
Although Sudan is considered as one of the countries with high prevalence rate (>8%) 4, 
like sub-Saharan Africa, China, Indonesia, , the Pacific islands, and Southeast Asia, this 
study shows moderate disease endemicity in Khartoum State. A study which was 
conducted in Omdurman Maternity Hospital among women during labor and cord blood 
from their newborns was screened; it was found that the prevalence of HBsAg was 4.1% 
among the women and 1.52% among the neonates .37 The same finding was noticed in 
eastern and northern Europe, Japan, the Mediterranean basin, the Middle East, Latin and 
South America, and central Asia4. This is can be attributed to the diverse ethnic  groups 
in the Sudan, that may have markedly different HBV prevalence.10 Similar phenomenon 
was obtained in a study that conducted to measure the prevalence of hepatitis B 'e' 
antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in pregnant women in the Gulf 
States, where results have shown that hepatitis B virus (HBV) prevalence in pregnant 
women is of intermediate endemicity in Oman and of low endemicity in Qatar and 
UAE,34 despite the fact that they are categorized as intermediate prevalence areas 14. On 
the other hand this moderate disease endemicity necessitates further studies in young 
children to assess the relative importance of perinatal versus childhood transmission10. 
Out of these 12 women who were HBsAg positive, only one woman found to be hepatitis 
B e antigen positive (8.3%). Distribution of HBV carriers in population due to perinatal 
infection was calculated using the efficacy of perinatal transmission10, which was 
measured as 80%, where the incidence of perinatal infection is around 70-90%, when the 
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mother is both HBsAg-positive and HBeAg-positive, this indicates that the likely 
importance of perinatal transmission is 0.25% (the result of multiplying the prevalence of 
HBsAg, HBeAg and the efficacy of transmission), which is low. This reflects that 
perinatal transmission is unlikely to play an important role in the mode of transmission of 
HBV in Khartoum State.  This result is similar to some cases in the Middle East as in 
Jizan of Saudi Arabia, where perinatal transmission was unlikely to play an important 
role in HBV hyperendemicity in Jizan area 24.Two studies conducted on mother-to-child 
transmission of HBV also in Saudi Arabia found the perinatal transmission to be 0.26% 
and 0.36% 24, respectively, which is similar to that in Khartoum State. In Kuwait the 
perinatal transmission was calculated as 0.16% which is low. In contrast many studies 
support the likely important role of perinatal transmission of HBV as the studies carried 
out in the Republic of Yemen and Egypt, where the calculated perinatal transmission was 
found to be 0.43% and 0.50% respectively24.  
Although Khartoum State appears to have low perinatal transmission, other areas in 
Sudan were shown to have high perinatal transmission rates as in Gazeera and Juba with 
more than 0.5% rates 35.  
Regarding the Scio-demographic factors of study population, most of them reside in 
Omdurman locality. All women were in the age group 15-49 years with a median age of 
27 years. Most of the study population was originally from the North and West Sudan 
which can explain the intermediate prevalence of hepatitis B because most studies in 
Sudan suggested that, there is a higher prevalence of HBV infection among residents of 
the South compared with those of the North .27 
All women involved in the study were married, but one and most of them have more than 
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three children forming large families. The majority of them were delivered vaginally at 
hospital. Nearly all were house wives and not involved in risky occupations like health 
workers, which indicates the importance of transmission during childhood . More than 
half of the study population has spent more than 9 years in systematic education. The 
investigator has observed that most of the women were not aware about the risk of 
hepatitis B disease and its mode of transmission.  
When relating risk factors which are; the age, education, race, risky occupation, history of 
jaundice, blood transfusion, and unsafe injection, to the prevalence of HBV, the relation 
was found to be statistically insignificant. The same results were obtained from a study 
conducted among pregnant women in Omdurman maternity hospitals, where history of 
jaundice, contact with jaundiced patient, blood transfusion past history of operation, 
tattooing contact with blood were found statistically insignificant37. 
This may be due to the fact that in most high and intermediate prevalence areas 
transmission, including that to the future mothers is predominantly due to perinatal 
transmission and during early childhood, this may weaken the relation of the studied risk 
factors to disease transmission12. Another point to be mentioned is that some of the risk 
factors involved in the study were sensitive to be told, and some are related to the 
husband’s history with expected recall bias or inaccurate information. In some low 
prevalence areas like in Canada Western Europe, New Zealand, sexual and percutaneous 
transmission during adulthood are the main routes of transmission but they were difficult 
to be identified12. Many studies in countries with low endemicity, such as Britain and 
North America, have looked at selective versus universal antenatal screening. When a 
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direct comparison has been made, selective screening failed to identify about half of the 
women whose babies were at risk. Among the reasons for the failure of selective systems 
is the difficulty of discussing risk behaviors in a busy antenatal clinic, the possibility that 
women with no risk factors might have been infected by a partner with a "risk history," 
and many infected women have no recognized risk factors. As a result of a study in the 
Netherlands the Dutch national health authority has adopted as a policy the non-selective 
screening for hepatitis B infection with tests for blood group and syphilis early in 
pregnancy38. In spite of the fact that most HBV infections in developed countries result 
from sexual activity, injection-drug use, or occupational exposure, household contact, 
renal dialysis, transmission from a surgeon, and receipt of organs or blood products, no 
clear risk factors are found in 20 to 30 percent of patients, perhaps because of reluctance 
to report high-risk12. 
The most common factors found to be associated with HBV infection and carrier status in 
the Middle East, other than the risk of perinatal transmission associated with 
HBsAg/HBeAg status of the mother, are family size, socioeconomic status, age, 
educational status and a history of previous blood transfusion, surgery or contact with a 
jaundiced person.24 
This study showed statistically insignificant relation between age and HBV positive 
status OR= 0.64; (95% CI. 0.164-2.527) this in part may be due to the similarity in age 
groups of the study population. Some studies suggested higher chances of HBsAg 
positivity in those who are between 20 and 29 years of age39.  
This study in African rooted race showed insignificant relation to HBsAg positive status 
with OR= 0.514 (95% CI. 0.139- 1.905). In comparison, a study in the United States of 
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America to estimate race/ethnicity-specific prevalence of hepatitis B surface antigen 
(HBsAg) in pregnant urban women and to evaluate factors associated with maternal 
HBsAg testing , showed that HBsAg prevalence among white non-Hispanics was 0.60% 
(95% confidence interval [CI]: 0.22–0.98), black non-Hispanics 0.97% (95% CI: 0.48–
1.47), Hispanics 0.14% (95% CI: 0.01–0.26), and Asians 5.79% (95% CI: 4.42–7.16)40.  
Large family size is a recognized risk factor for HBV transmission. This study showed 
that 28% of the study population have more than 3 children (large size families) and 
when related to HBsAg positivity, this read 2.202 OR (95% CI. 0.356- 13.610). Evidence 
supporting the role of large family size in increasing the risk of HBV infection came from 
the observation of pronounced familial clustering of HBV infection in Jordan. A 
significant correlation was found between family size and the proportion of HBsAg-
positive family members24.  
No significant relation is detected between the level of education and HBV transmission 
in Khartoum state, but higher rates found in mothers with low educational status in Egypt 
and a negative correlation between prevalence of HBV infection and educational levels 
has been observed in the Islamic Republic of Iran24.  
Only 2.8% of the study population was employed in risky occupations mainly as health 
workers. Healthcare workers, have the highest risks of HBV infection32. The prevalence 
of hepatitis B virus infection was estimated to be 6 % among health workers at Khartoum 
state 29.  
History of jaundice, blood transfusion, and unsafe injection, and renal dialysis were 
weakly related to HBV transmission in this study, and this differs from the situation in 
Middle East where they were found to be associated with HBV infection and carrier 
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status24. Recently blood transfusion is hardly a factor in transmitting HBV due to pre 
transfusion screening.    
The same can be said when discussing the risk factors associated to the husband where 
weak relation with HBsAg positivity was observed. This can be due to the inaccuracy of 
stating information related to husbands, beside, some points were unlikely to be talked 







































Khartoum state was found to be of intermediate endemicity for hepatitis B virus 
infection. Frequency of HBV carriers in population due to perinatal infection was low 
which reflects that perinatal transmission is unlikely to play an important role in the mode 
of transmission of HBV in Khartoum State. Most of the study population resides in 
Omdurman locality.  
All women were in the age group 15-49 years with a median age of 27 years. Most of the 
study population was originally from the North and West Sudan  which can explain the 
intermediate prevalence of hepatitis B because most studies in Sudan suggested that there 
is a higher prevalence of HBV infection among residents of the South compared with 
those of the North .4 
All women involved in the study were married; most of them have more than 3 children. 
The majority of them were delivered vaginally at hospital. Nearly all were house wives 
and not involved in risky occupations like health workers, which indicates the importance 
of transmission during childhood. More than half of the study population has spent more 
than 9 years in systematic education. 
All risk factors found to be statistically insignificant with  the prevalence of hepatitis B 
virus infection ,which may be due to the fact that in most high and intermediate 









* To continue giving the HBV vaccine with the DPT as scheduled in Khartoum State. 
* To conduct other studies for young children to define the relative importance of      
    perinatal versus childhood transmission Khartoum State. 
* To screen all pregnant women for HBV during antenatal care visits, and giving  
   appropriate management for neonates of positive mothers. 
* To health educate pregnant women about hepatitis B infection (risk factors and mode of   
   transmission) at antenatal care visits. 
* To conduct another community based studies to estimate the prevalence. 
* To study the prevalence in other states. 
* To vaccinate female adolescents (child bearing age) before pregnancy to minimize  
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  ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
  وزارة اﻟﺼﺤﺔ وﻻﻳﺔ اﻟﺨﺮﻃﻮم
  ﻗﺴﻢ اﻟﺒﺤﻮث-اﻹدارة اﻟﻌﺎﻣﺔ ﻟﻠﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ اﻷوﻟﻴﺔ 
  إﻗﺮار ﻣﻮاﻓﻘﺔ
  
وﺳﻂ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ ﺑﻮﻻﻳﺔ ( ب)ﺑﺤﺚ ﻧﺴﺒﺔ اﻧﺘﺸﺎر ﻣﺮض اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﻴﺮوﺳﻲ / اﻟﻤﻮﺿﻮع 
  4002اﻟﺨﺮﻃﻮم 
  
 
ﺑﺎﻟﻤﻮاﻓﻘﺔ ﻋﻠﻲ ﻣﺸﺎرآﺘﻲ ﻓﻲ اﻟﺪراﺳﺔ ﺑﻌﺪ ﻓﻬﻢ اهﺪاف اﻟﺪراﺳﺔ آﻤﺎ اواﻓﻖ ....... ......................................اﻗﺮ أﻧﺎ
آﻤﺎ أواﻓﻖ ﻋﻠﻲ اﺧﻄﺎري ﻓﻲ  ﺣﺎﻟﺔ آﺎن اﻟﻨﺘﻴﺠﺔ إﻳﺠﺎﺑﻴﺔ و ﻣﻌﺮﻓﺔ آﻴﻔﻴﺔ اﺧﺬ ،ﻣﻨﻲ (  س س 5)ﻋﻠﻲ أﺧﺬ ﻋﻴﻨﺔ دم 
  .اﻻﺣﺘﻴﺎﻃﺎت اﻟﻼزﻣﺔ 
  :.....................................................اﻻﺳﻢ •
 :..................................................ﻀﺎءاﻹﻣ •
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  ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
  ﻗﺴﻢ اﻟﺒﺤﻮث - اﻹدارة اﻟﻌﺎﻣﺔ ﻟﻠﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ اﻷوﻟﻴﺔ -وزارة اﻟﺼﺤﺔ وﻻﻳﺔ اﻟﺨﺮﻃﻮم 
وﺳﻂ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ ﺑﻮﻻﻳﺔ ( ب)ﻲ اﺳﺘﻤﺎرة ﺑﺤﺚ ﻧﺴﺒﺔ اﻧﺘﺸﺎر ﻣﺮض اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻔﻴﺮوﺳ
 5002اﻟﺨﺮﻃﻮم 
  :اﻟﺠﺰء اﻷول •
 :اﻟﻤﺤﻠﻴﺔ •
 :.........................................................................اﺳﻢ اﻟﻤﺮآﺰ  •
 :........................................................................ﻧﻮع اﻟﻤﺮآﺰ  •
  .......................................................................:...رﻗﻢ اﻟﻤﺘﺴﻠﺴﻞ  •
  :اﻟﻌﻮاﻣﻞ اﻻﺟﺘﻤﺎﻋﻴﺔ: اﻟﺠﺰء اﻟﺜﺎﻧﻲ 
 :...................................................................................... اﻟﻌﻤﺮ  •
 :ﺗﻮد ﻣﻌﺮﻓﺔ اﻟﻨﺘﻴﺠﺔ  •
  ﻻ-2ﻧﻌﻢ                       -1
 :........................................................................................اﻟﺴﻜﻦ  •
 :............................................ ......................ﻧﻤﺮة اﻟﺘﻠﻔﻮن  •
  .............:......................................................................اﻟﻘﺒﻴﻠﺔ •
 :اﻟﻮﻃﻦ اﻷﺻﻠﻲ •
 :.............................................داﺧﻞ اﻟﺴﻮدان ﺣﺪد اﻟﻮﻻﻳﺔ -1
 :..................................................................................ﺧﺎرﺟﺎﻟﺴﻮداﻧﺤﺪد اﻟﺒﻠﺪ-2
 .اﻟﺤﺎﻟﺔ اﻻﺟﺘﻤﺎﻋﻴﺔ  •
  ﻏﻴﺮ ﻣﺘﺰوﺟﺔ-4أرﻣﻠﺔ               -3           ﻣﻄﻠﻘﺔ    -2ﻣﺘﺰوﺟﺔ        -1
 ﻋﻨﺪك آﻢ ﻃﻔﻞ ؟ •
  3  أآﺜﺮ ﻣﻦ -3    3-1 -2 وﻻ واﺣﺪ  -1
 آﻴﻒ آﺎﻧﺖ وﻻداﺗﻚ اﻟﺴﺎﺑﻘﺔ ؟، اذا آﺎن ﻋﻨﺪك ﻃﻔﻞ او اآﺜﺮ  •
   ﻻ ﻳﻨﻄﺒﻖ -4آﻠﻬﺎ ﻗﻴﺼﺮي   - -3آﻠﻬﺎ ﻃﺒﻴﻌﻲ          -2ﻃﺒﻴﻌﻲ و ﻗﻴﺼﺮي                -1 •
 اﻳﻦ ﺗﻤﺖ اﻟﻮﻻدة ؟، اذا آﻨﺖ وﻟﺪﺗﻲ ﻃﺒﻴﻌﻲ ﻣﻦ ﻗﺒﻞ . •
   ﻻ ﻳﻨﻄﺒﻖ -3 اﻟﻤﺴﺘﺸﻔﻲ                  -2اﻟﺒﻴﻦ             -1
 :اﻟﺘﻌﻠﻴﻢ  •
  ﺟﺎﻣﻌﻲ-6ﺛﺎﻧﻮي           -5ﻣﺘﻮﺳﻂ        -4اﺑﺘﺪاﺋﻲ     – 3ﺧﻠﻮة     -2ﻏﻴﺮ ﻣﺘﻌﻠﻤﺔ    -1
  ﻓﻮق اﻟﺠﺎﻣﻌﻲ-7 
 :ﺗﻌﻠﻴﻢ اﻟﺰوج •
  ﺟﺎﻣﻌﻲ-6ﺛﺎﻧﻮي           -5ﻣﺘﻮﺳﻂ        -4اﺑﺘﺪاﺋﻲ     – 3ﺧﻠﻮة     -2ﻏﻴﺮ ﻣﺘﻌﻠﻢ   -1
  ﻓﻮق اﻟﺠﺎﻣﻌﻲ-7 
 :اﻟﻤﻬﻨﺔ  •
    * ﻋﺎﻣﻠﺔ ﻓﻲ اﻟﻤﺠﺎل اﻟﺼﺤﻲ-2رﺑﺔ ﻣﻨﺰل       -1
 ..............................................................  ﺣﺪدي، اﺧﺮي  -2
 :ﻣﻬﻨﺔ اﻟﺰوج  •
 ﺳﺎﺋﻖ ﻣﺴﺎﻓﺎت ﻃﻮﻳﻠﺔ  -3 او اﻟﺸﺮﻃﺔ    ﻳﻌﻤﻞ ﺑﺎﻟﺠﻴﺶ-2*    ﻋﺎﻣﻞ ﺻﺤﻲ -1
 .ﻻ ﻳﻌﻤﻞ  -2
 ...............................................................ﺣﺪدي،أﺧﺮي  -3
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  :ﻋﻮاﻣﻞ اﻟﺨﻄﻮرة : اﻟﺠﺰء اﻟﺜﺎﻟﺚ
  ؟هﻞ ﺗﻢ ﻟﻚ ﻧﻘﻞ دم ﻣﻦ ﻗﺒﻞ •
  ﻻ اﻋﺮف- 3ﻻ              -2ﻧﻌﻢ                       -1
 هﻞ ﺗﻢ ﻟﺰوﺟﻚ ﻧﻘﻞ دم ﻣﻦ ﻗﺒﻞ ؟ •
  ﻻ اﻋﺮف- 3ﻻ                     -2           ﻧﻌﻢ       -1
اﻟﻄﻌﻦ ﺑﺎﺑﺮة ) هﻞ ﺗﻌﺮﺿﺖ ﻷي ﻧﻮع ﻣﻦ اﻟﺤﻘﻦ اﻟﻤﻠﻮث
ﺣﺎدث ، ﻣﻮس ﻣﺴﺘﻌﻤﻞ ، ﺳﻜﻴﻦ ﻣﻠﻮث . ﻣﺴﺘﻌﻤﻠﺔ 
 **ﻣﻦ ﻗﺒﻞ ؟( ﻋﺮﺑﻴﺔ
  ﻻ اﻋﺮف- 3ﻻ             -2 ﻧﻌﻢ                         -1
اﻟﻄﻌﻦ ) هﻞ ﺗﻌﺮض زوﺟﻚ ﻷي ﻧﻮع ﻣﻦ اﻟﺤﻘﻦ اﻟﻤﻠﻮث
ﺣﺎدث ، ﻣﻮس ﻣﺴﺘﻌﻤﻞ ، ﺳﻜﻴﻦ ﻣﻠﻮث . ﺑﺎﺑﺮة ﻣﺴﺘﻌﻤﻠﺔ 
 **ﻣﻦ ﻗﺒﻞ ؟( ﻋﺮﺑﻴﺔ
  ﻻ اﻋﺮف- 3ﻻ                 -2ﻧﻌﻢ                  
  هﻞ أﺻﺒﺖ ﺑﻤﺮض اﻟﻴﺮﻗﺎن ﻣﻦ ﻗﺒﻞ ؟
  ﻻ اﻋﺮف- 3ﻻ           -2 ﻧﻌﻢ                       -1
 هﻞ أﺻﻴﺐ زوﺟﻚ ﺑﻤﺮض اﻟﻴﺮﻗﺎن ﻣﻦ ﻗﺒﻞ ؟ •
  ﻻ اﻋﺮف- 3ﻻ          -2               ﻧﻌﻢ           -1
 (ﻏﺴﻴﻞ آﻠﻲ )هﻞ أﻧﺖ ﻣﺼﺎﺑﺔ ﺑﺄي ﻣﺮض ﻣﺰﻣﻦ ﻳﺴﺘﻮﺟﺐ اﻟﺤﻘﻦ اﻟﺪوري •
  ﻻ اﻋﺮف- 3ﻻ         -2 ﻧﻌﻢ                      -1
 إذا آﺎﻧﺖ اﻹﺟﺎﺑﺔ ﺑﻨﻌﻢ ﺣﺪد ﻧﻮع اﻟﻤﺮض •
  اﻟﺴﻞ-4 ﺳﻜﺮي -3 أﻣﺮاض اﻟﺪم اﻟﻤﺰﻣﻨﺔ  -2ﻓﺸﻞ آﻠﻮي     -1
 ............................................................أﺧﺮى ﺣﺪد -2
  ﻻ ﻳﻨﻄﺒﻖ  -3
 هﻞ زوﺟﻚ ﻣﺼﺎب ﺑﺄي ﻣﺮض ﻣﺰﻣﻦ ﻳﺴﺘﻮﺟﺐ اﻟﺤﻘﻦ اﻟﺪوري •
 ﻻ اﻋﺮف- 3 ﻻ                 -2 ﻧﻌﻢ                      -1 •
 إذا آﺎﻧﺖ اﻹﺟﺎﺑﺔ ﺑﻨﻌﻢ ﺣﺪد ﻧﻮع اﻟﻤﺮض •
 ﻞ اﻟﺴ-4 ﺳﻜﺮي -3 أﻣﺮاض اﻟﺪم اﻟﻤﺰﻣﻨﺔ  -2 ﻓﺸﻞ آﻠﻮي    1 -3
 ............................................................أﺧﺮى ﺣﺪد -4
  ﻻ ﻳﻨﻄﺒﻖ  -5
 هﻞ زوﺟﻚ ﻣﺘﺰوج ﻏﻴﺮك ؟
  ﻧﻌﻢ  -1
  ﻻ  -2
  ﻻ اﻋﺮف- 3
 
 ﻓﻲ ﺣﺎﻟﺔ اﻹﺟﺎﺑﺔ ﺑﻨﻌﻢ آﻢ زوﺟﺔ ﻟﺪﻳﻪ ﻏﻴﺮك  ؟ •
  ﻻ ﻳﻨﻄﺒﻖ -5 أآﺜﺮ ﻣﻦ ﺛﻼﺛﺔ   -4 ﺛﻼﺛﺔ    -3 اﺛﻨﺘﺎن   -2واﺣﺪة    -1
  اﻟﻮﺑﺎﺋﻲ ﻣﻦ ﻗﺒﻞ ؟هﻞ ﺗﻄﻌﻤﺘﻲ ﻣﻦ اﻟﺘﻬﺎب اﻟﻜﺒﺪ •
  ﻻ اﻋﺮف- 3 ﻻ      -2ﻧﻌﻢ                          .1
  ادا آﺎﻧﺖ اﻻﺟﺎﺑﺔ ﻧﻌﻢ آﻢ ﺟﺮﻋﺔ اﺧﺪت ؟
   ﻻ ﻳﻨﻄﺒﻖ       -4 ﺛﻼﺛﺔ         -3 اﺛﻨﻴﻦ             -2واﺣﺪة       -1
  
   
 37
 
 هﻞ ﺗﻢ ﻟﻚ ﻓﺤﺺ ﻻﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﺒﺎﺋﻲ ﻣﻦ ﻗﺒﻞ ؟ •
  ﻻ اﻋﺮف- 3     ﻻ -2ﻧﻌﻢ                          -1
  ﻣﺎدا آﺎﻧﺖ اﻟﻨﺘﻴﺠﺔ ؟، ادا آﺎﻧﺖ اﻻﺟﺎﺑﺔ ﻧﻌﻢ 
    ﻻ ﻳﻨﻄﺒﻖ -3 ﺳﻠﺒﻴﺔ         -2اﻳﺠﺎﺑﻴﺔ      -1
   (gAsbH: )ﻧﺘﻴﺠﺔ ﻓﺤﺺ اﻟﺪم  •
     اﻳﺠﺎﺑﻴﺔ-1
   ﺳﻠﺒﻴﺔ-2
   (gAebH: )ﻧﺘﻴﺠﺔ ﻓﺤﺺ اﻟﺪم  •
     اﻳﺠﺎﺑﻴﺔ-1




 ﻓﻨﻲ ﻣﻌﻤﻞ – زاﺋﺮة ﺻﺤﻴﺔ – داﻳﺔ – ﺳﺴﺘﺮ –ﻣﻤﺮض  –ﻣﺴﺎﻋﺪ ﻃﺒﻲ ، ﻃﺒﻴﺐ : ﻋﺎﻣﻞ او ﻋﺎﻣﻠﺔ ﻓﻲ اﻟﻤﺠﺎل اﻟﺼﺤﻲ *
 .


























The centers were divided as follow: 




Sample of women/ 
antenatal care Unit 
1 Governmental Health centre   6 94 
2 NGOS Health centre  10 157 
3 hospitals   4 64 




Centers per locality were divided as follow: 








Locality  No  
3 1  -  2  Khartoum  1 
3 1  2  -  Jabal awlia  2 
4 1  1  2  Bahry 3 
3 -  2  1  Sharg Alnil 4 
3 1  1  1  Omdurman 5 
1 -  1  -  Karrary 6 
3 -  3  -  Umbada 7 
20 4  10  6 Total 8
 
 
